Connect with us

Technology

Veeva Announces Fiscal 2027 Second Quarter Results

Published

on

Total Revenues of $928.0M, up 18% Year Over Year
Subscription Revenues of $766.8M, up 16% Year Over Year

PLEASANTON, Calif., Aug. 26, 2026 /PRNewswire/ — Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its second quarter ended July 31, 2026.

“AI is opening up the next big chapter for Veeva and life sciences,” said CEO Peter Gassner. “Vault CRM had its best quarter ever and Veeva Falcon accelerated rapidly. By bringing together deep industry applications, agents, data, and consulting, we are helping the industry drive new efficiencies from clinical to commercial and deliver better outcomes for patients.”

Fiscal 2027 Second Quarter Results:

Revenues: Total revenues for the second quarter were $928.0 million, up from $789.1 million one year ago, an increase of 18% year over year. Subscription revenues for the second quarter were $766.8 million, up from $659.2 million one year ago, an increase of 16% year over year.Operating Income and Non-GAAP Operating Income:(1) Second quarter operating income was $275.0 million, compared to $195.9 million one year ago, an increase of 40% year over year. Non-GAAP operating income for the second quarter was $415.9 million, compared to $352.6 million one year ago, an increase of 18% year over year.Net Income and Non-GAAP Net Income:(1) Second quarter net income was $273.4 million, compared to $200.3 million one year ago, an increase of 37% year over year. Non-GAAP net income for the second quarter was $387.4 million, compared to $333.4 million one year ago, an increase of 16% year over year.Net Income per Share and Non-GAAP Net Income per Share:(1) For the second quarter, fully diluted net income per share was $1.66, compared to $1.19 one year ago, while non-GAAP fully diluted net income per share was $2.35, compared to $1.99 one year ago.

“Second quarter results exceeded guidance on all metrics and our view for the full year improved across the board,” said CFO Brian Van Wagener. “We continue to execute well across the business while also accelerating innovation and progress in new growth areas.”

Recent Highlights:

Vault CRM Leadership Grows with More Top 20 Wins, Go-lives, and AI Adoption – Vault CRM leadership grew with more than 180 customers live, including five top 20 biopharmas. In August, two top 20 biopharmas and one large enterprise biopharma committed to Vault CRM, bringing total top 20 commitments to 12 globally. As the industry’s fastest path to agentic CRM, a top 20 biopharma deployed Vault CRM and the Agentic Call Report across its full U.S. field team in the quarter.Major AI Milestones for Vault AI and Falcon, and Agentic MLR Launches – Veeva AI advanced rapidly across all areas. Development of Veeva Falcon, the agentic labor platform for clinical, regulatory, and safety, is moving quickly with five early adopters and on track for initial go-lives this year. The company also acquired Copli in the quarter and launched Veeva Falcon MLR to automate content reviews. August marked a major milestone for Vault AI with new standard agents, broader capabilities for existing agents, and advanced tools for custom agent development.Delivering the Connected Foundation for R&D and Quality – Development Cloud and Quality Cloud saw broad adoption, deepening relationships with new and existing customers. In clinical, a large enterprise biopharma selected Veeva EDC, building on its existing eTMF, CTMS, and Study Startup foundation. Veeva Safety surpassed 100 total customers while securing its second top 20 biopharma win for Safety Workbench. In Quality, Veeva added more than 30 new customers, driven by 20 or more wins each across QualityDocs, QMS, and Training.

Financial Outlook:

Veeva is providing guidance for its fiscal third quarter ending October 31, 2026 as follows:

Total revenues between $932 and $935 million.Non-GAAP operating income between $417 and $420 million.(2)Non-GAAP fully diluted net income per share between $2.33 and $2.34.(2)

Veeva is providing updated guidance for its fiscal year ending January 31, 2027 as follows:

Total revenues between $3,682 and $3,687 million.Non-GAAP operating income of about $1,640 million.(2)Non-GAAP fully diluted net income per share of approximately $9.21.(2)

Conference Call Information

Prepared remarks and an investor presentation providing additional information and analysis can be found on Veeva’s investor relations website at ir.veeva.com. Veeva will host a Q&A conference call at 2:00 p.m. PT today, August 26, 2026, and a replay of the call will be available on Veeva’s investor relations website.

What:

Veeva Systems Fiscal 2027 Second Quarter Results Conference Call

When:

Wednesday, August 26, 2026

Time:

2:00 p.m. PT (5:00 p.m. ET)

Online Registration:

https://events.q4inc.com/analyst/883220744?pwd=7dXQ6ZuG 

Webcast:

ir.veeva.com

(1) This press release uses non-GAAP financial metrics that are adjusted for the impact of various GAAP items. See the section titled “Non-GAAP Financial Measures” and the tables entitled “Reconciliation of GAAP to Non-GAAP Financial Measures” below for details.

(2) Veeva is not able, at this time, to provide GAAP targets for operating income and fully diluted net income per share for the third fiscal quarter ending October 31, 2026 or the fiscal year ending January 31, 2027 because of the difficulty of estimating certain items excluded from non-GAAP operating income and non-GAAP fully diluted net income per share that cannot be reasonably predicted, such as charges related to stock-based compensation expense. The effect of these excluded items may be significant.

About Veeva Systems

Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders and the industries it serves. For more information, visit veeva.com.

Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website in addition to following our press releases, SEC filings, and public conference calls and webcasts.

Forward-looking Statements

This release contains forward-looking statements regarding Veeva’s expected future performance and, in particular, includes quotes from management and guidance, provided as of August 26, 2026, about Veeva’s expected future financial results. Estimating guidance accurately for future periods is difficult. It involves assumptions and internal estimates that may prove to be incorrect and is based on plans that may change. Hence, there is a significant risk that actual results could differ materially from the guidance we have provided in this release and we have no obligation to update such guidance. There are also numerous risks that have the potential to negatively impact our financial performance, including issues related to the performance, availability, security, or privacy of our products, competitive factors, customer decisions and priorities, developments that impact the life sciences industry (including regulatory, funding, or policy changes), general macroeconomic and geopolitical events (including changes in trade policy or practices, inflationary pressures, currency exchange fluctuations, changes in interest rates, and geopolitical conflicts), and issues that impact our ability to hire, retain and adequately compensate talented employees. We have summarized what we believe are the principal risks to our business in a section titled “Summary of Risk Factors” on pages 33 and 34 in our filing on Form 10-Q for the period ended April 30, 2026 which you can find here. Additional details on the risks and uncertainties that may impact our business can be found in the same filing on Form 10-Q and in our subsequent SEC filings, which you can access at sec.gov. We recommend that you familiarize yourself with these risks and uncertainties before making an investment decision.

Investor Relations Contact:

Media Contact:

Gunnar Hansen

Maria Scurry

Veeva Systems Inc.

Veeva Systems Inc.

267-460-5839

781-366-7617

ir@veeva.com

pr@veeva.com

 

VEEVA SYSTEMS INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

July 31,
2026

January 31,
2026

Assets

Current assets:

Cash and cash equivalents

$    1,812,012

$    1,421,233

Short-term investments

5,430,935

5,139,581

Accounts receivable, net

496,677

1,259,737

Unbilled accounts receivable

68,970

50,609

Prepaid expenses and other current assets

137,633

126,470

Total current assets

7,946,227

7,997,630

Property and equipment, net

79,483

70,261

Deferred costs, net

27,835

29,961

Lease right-of-use assets

129,320

75,626

Goodwill

492,991

439,877

Intangible assets, net

55,647

30,314

Deferred income taxes

268,250

273,417

Other long-term assets

60,470

62,257

Total assets

$    9,060,223

$    8,979,343

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$       35,977

$       37,644

Accrued compensation and benefits

42,188

45,857

Accrued expenses and other current liabilities

49,634

45,885

Income tax payable

3,018

6,698

Deferred revenue

1,310,498

1,488,819

Lease liabilities

14,635

12,153

Total current liabilities

1,455,950

1,637,056

Deferred income taxes

2,056

558

Long-term lease liabilities

137,060

83,706

Other long-term liabilities

33,708

43,271

Total liabilities

1,628,774

1,764,591

Stockholders’ equity:

Common stock

2

2

Additional paid-in capital

2,579,728

2,843,089

Accumulated other comprehensive (loss) income

(46,147)

8,160

Retained earnings

4,897,866

4,363,501

Total stockholders’ equity

7,431,449

7,214,752

Total liabilities and stockholders’ equity

$    9,060,223

$    8,979,343

 

VEEVA SYSTEMS INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands, except per share data)

(Unaudited)

Three months ended July 31,

Six months ended July 31,

2026

2025

2026

2025

Revenues:

Subscription(3)

$      766,764

$      659,183

$    1,496,939

$    1,293,951

Professional services and other(4)

161,199

129,898

313,972

254,173

Total revenues

927,963

789,081

1,810,911

1,548,124

Cost of revenues(5):

Cost of subscription

105,677

93,830

204,780

172,176

Cost of professional services and other

126,335

101,423

248,156

196,901

Total cost of revenues

232,012

195,253

452,936

369,077

Gross profit

695,951

593,828

1,357,975

1,179,047

Operating expenses(5):

Research and development

222,918

192,677

431,241

376,710

Sales and marketing

126,701

109,439

237,818

208,067

General and administrative

71,314

95,804

140,786

164,630

Total operating expenses

420,933

397,920

809,845

749,407

Operating income

275,018

195,908

548,130

429,640

Other income, net

74,512

69,456

148,930

134,545

Income before income taxes

349,530

265,364

697,060

564,185

Income tax provision

76,101

65,055

162,695

135,686

Net income

$      273,429

$      200,309

$      534,365

$      428,499

Net income per share:

Basic

$          1.68

$          1.23

$          3.28

$          2.63

Diluted

$          1.66

$          1.19

$          3.22

$          2.56

Weighted-average shares used to compute net income per share:

Basic

162,344

163,496

162,836

163,129

Diluted

165,057

167,685

166,072

167,272

Other comprehensive income:

Net change in unrealized (loss) gain on available-for-sale investments

$      (26,490)

$      (11,300)

$      (53,941)

$        6,067

Net change in cumulative foreign currency translation gain (loss)

135

390

(366)

352

Comprehensive income

$      247,074

$      189,399

$      480,058

$      434,918

(3) Includes subscription revenues from the following product areas:

Veeva Commercial Solutions

$      347,389

$      307,523

$      685,255

$      612,934

Veeva R&D and Quality Solutions

419,375

351,660

811,684

681,017

Total subscription

$      766,764

$      659,183

$    1,496,939

$    1,293,951

(4) Includes professional services and other revenues from the following product areas:

Veeva Commercial Solutions

$       59,742

$       47,703

$      117,315

$       94,270

Veeva R&D and Quality Solutions

101,457

82,195

196,657

159,903

Total professional services and other

$      161,199

$      129,898

$      313,972

$      254,173

(5) Includes stock-based compensation as follows:

Cost of revenues:

Cost of subscription

$        2,224

$        1,941

$        3,985

$        3,656

Cost of professional services and other

15,939

14,804

30,090

27,573

Research and development

62,220

53,388

113,783

101,337

Sales and marketing

27,886

25,392

52,480

47,713

General and administrative

28,534

26,441

55,724

53,897

Total stock-based compensation

$      136,803

$      121,966

$      256,062

$      234,176

 

VEEVA SYSTEMS INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

Six months ended July 31,

2026

2025

Cash flows from operating activities

Net income

$     534,365

$     428,499

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

22,458

19,948

Reduction of lease right-of-use assets

7,038

6,316

Accretion of discount on short-term investments

(2,841)

(4,535)

Stock-based compensation

256,062

234,176

Amortization of deferred costs

9,805

8,205

Deferred income taxes

26,529

31,699

Other, net

(1,127)

(1,414)

Changes in operating assets and liabilities:

Accounts receivable

768,314

593,032

Unbilled accounts receivable

(18,361)

(9,587)

Deferred costs

(7,679)

(7,721)

Prepaid expenses and other current and long-term assets

(21,394)

(21,232)

Accounts payable

(652)

3,361

Accrued expenses and other current liabilities

(1,578)

23,763

Income tax payable

(3,945)

(5,362)

Deferred revenue

(200,001)

(180,888)

Lease liabilities

(4,426)

(5,300)

Other long-term liabilities

3,258

2,631

Net cash provided by operating activities

1,365,825

1,115,591

Cash flows from investing activities

Purchases of short-term investments

(1,706,632)

(1,452,857)

Maturities and sales of short-term investments

1,345,987

1,023,691

Long-term assets

(9,773)

(12,213)

Acquisitions, net of cash acquired

(81,833)

—

Net cash used in investing activities

(452,251)

(441,379)

Cash flows from financing activities

Proceeds from exercise of common stock options

17,143

182,297

Repurchases of common stock

(472,673)

—

Taxes paid related to net share settlement of equity awards

(66,304)

(46,228)

Net cash (used in) provided by financing activities

(521,834)

136,069

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

(831)

1,365

Net change in cash, cash equivalents, and restricted cash

390,909

811,646

Cash, cash equivalents, and restricted cash at beginning of period

1,423,412

1,120,963

Cash, cash equivalents, and restricted cash at end of period

$   1,814,321

$   1,932,609

Supplemental disclosures of other cash flow information:

Excess tax (deficiency) benefit from employee stock plans

$        (824)

$      15,610

Non-GAAP Financial Measures

In Veeva’s public disclosures, Veeva has provided non-GAAP measures, which it defines as financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. In addition to its GAAP measures, Veeva uses these non-GAAP financial measures internally for budgeting and resource allocation purposes and in analyzing its financial results. For the reasons set forth below, Veeva believes that excluding the following items provides information that is helpful in understanding its operating results, evaluating its future prospects, comparing its financial results across accounting periods, and comparing its financial results to its peers, many of which provide similar non-GAAP financial measures.

Excess tax benefit (deficiency). Excess tax benefits (deficiencies) from employee stock plans are dependent on previously agreed-upon equity grants to our employees, vesting of those grants, stock price, and exercise behavior of our employees, which can fluctuate from quarter to quarter. Because these fluctuations are not directly related to our business operations, Veeva finds it useful to exclude excess tax benefits (deficiencies) when assessing the level of cash provided by operating activities. Given the nature of the excess tax benefits (deficiencies), Veeva believes excluding it allows investors to make meaningful comparisons between our operating cash flows from quarter to quarter and those of other companies.Stock-based compensation expenses. Veeva excludes stock-based compensation expenses primarily because they are non-cash expenses that Veeva excludes from its internal management reporting processes. Veeva’s management also finds it useful to exclude these expenses when they assess the appropriate level of various operating expenses and resource allocations when budgeting, planning and forecasting future periods. Moreover, because of varying available valuation methodologies, subjective assumptions and the variety of award types that companies can use, Veeva believes excluding stock-based compensation expenses allows investors to make meaningful comparisons between our recurring core business operating results and those of other companies.Amortization of purchased intangibles. Veeva incurs amortization expense for purchased intangible assets in connection with acquisitions of certain businesses and technologies. Amortization of intangible assets is a non-cash expense and is inconsistent in amount and frequency because it is significantly affected by the timing, size of acquisitions and the inherent subjective nature of purchase price allocations. Because these costs have already been incurred and cannot be recovered, and are non-cash expenses, Veeva excludes these expenses for its internal management reporting processes. Veeva’s management also finds it useful to exclude these charges when assessing the appropriate level of various operating expenses and resource allocations when budgeting, planning and forecasting future periods. Investors should note that the use of intangible assets contributed to Veeva’s revenues earned during the periods presented and will contribute to Veeva’s future period revenues as well.Litigation settlement-related charges. We exclude certain costs related to litigation settlements, including outcome-based payments to the law firms that represented us, because they are non-recurring and outside the ordinary course of business. Because these costs are unrelated to our day-to-day business operations, we believe excluding them enables more consistent evaluation of our operating results.Income tax effects on the difference between GAAP and non-GAAP costs and expenses. The income tax effects that are excluded relate to the imputed tax impact on the difference between GAAP and non-GAAP costs and expenses due to stock-based compensation and purchased intangibles for GAAP and non-GAAP measures.

There are limitations to using non-GAAP financial measures because non-GAAP financial measures are not prepared in accordance with GAAP and may be different from non-GAAP financial measures provided by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact upon our reported financial results. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by Veeva’s management about which items are adjusted to calculate its non-GAAP financial measures. Veeva compensates for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis and also by providing GAAP measures in its public disclosures.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Veeva encourages its investors and others to review its financial information in its entirety, not to rely on any single financial measure to evaluate its business, and to view its non-GAAP financial measures in conjunction with the most directly comparable GAAP financial measures. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables below.

VEEVA SYSTEMS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(Dollars in thousands)

(Unaudited)

The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

Reconciliation of Net Cash Provided by Operating Activities (GAAP basis to non-GAAP basis)

Three months ended July 31,

Six months ended July 31,

2026

2025

2026

2025

Net cash provided by operating activities on a GAAP basis

$    238,709

$    238,433

$  1,365,825

$  1,115,591

Excess tax (benefit) deficiency from employee stock plans

(3,268)

(13,031)

824

(15,610)

Net cash provided by operating activities on a non-GAAP basis

$    235,441

$    225,402

$  1,366,649

$  1,099,981

Net cash used in investing activities on a GAAP basis

$    (63,540)

$   (389,272)

$   (452,251)

$   (441,379)

Net cash (used in) provided by financing activities on a GAAP basis

$   (259,308)

$    115,689

$   (521,834)

$    136,069

Reconciliation of Financial Measures (GAAP basis to non-GAAP basis)

Three months ended July 31,

Six months ended July 31,

2026

2025

2026

2025

Cost of subscription revenues on a GAAP basis

$    105,677

$     93,830

$    204,780

$    172,176

Stock-based compensation expense

(2,224)

(1,941)

(3,985)

(3,656)

Amortization of purchased intangibles

(1,072)

(1,046)

(1,746)

(2,058)

Cost of subscription revenues on a non-GAAP basis

$    102,381

$     90,843

$    199,049

$    166,462

Gross margin on subscription revenues on a GAAP basis

86.2 %

85.8 %

86.3 %

86.7 %

Stock-based compensation expense

0.3

0.3

0.3

0.3

Amortization of purchased intangibles

0.1

0.1

0.1

0.1

Gross margin on subscription revenues on a non-GAAP basis

86.6 %

86.2 %

86.7 %

87.1 %

Cost of professional services and other revenues on a GAAP basis

$    126,335

$    101,423

$    248,156

$    196,901

Stock-based compensation expense

(15,939)

(14,804)

(30,090)

(27,573)

Amortization of purchased intangibles

—

(139)

—

(273)

Cost of professional services and other revenues on a non-GAAP basis

$    110,396

$     86,480

$    218,066

$    169,055

Gross margin on professional services and other revenues on a GAAP basis

21.6 %

21.9 %

21.0 %

22.5 %

Stock-based compensation expense

9.9

11.4

9.5

10.8

Amortization of purchased intangibles

—

0.1

—

0.2

Gross margin on professional services and other revenues on a non-GAAP basis

31.5 %

33.4 %

30.5 %

33.5 %

Gross profit on a GAAP basis

$    695,951

$    593,828

$  1,357,975

$  1,179,047

Stock-based compensation expense

18,163

16,745

34,075

31,229

Amortization of purchased intangibles

1,072

1,185

1,746

2,331

Gross profit on a non-GAAP basis

$    715,186

$    611,758

$  1,393,796

$  1,212,607

Gross margin on total revenues on a GAAP basis

75.0 %

75.3 %

75.0 %

76.2 %

Stock-based compensation expense

2.0

2.1

1.9

2.0

Amortization of purchased intangibles

0.1

0.1

0.1

0.1

Gross margin on total revenues on a non-GAAP basis

77.1 %

77.5 %

77.0 %

78.3 %

Research and development expense on a GAAP basis

$    222,918

$    192,677

$    431,241

$    376,710

Stock-based compensation expense

(62,220)

(53,388)

(113,783)

(101,337)

Amortization of purchased intangibles

(270)

—

(270)

—

Research and development expense on a non-GAAP basis

$    160,428

$    139,289

$    317,188

$    275,373

 

VEEVA SYSTEMS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (continued)

(Dollars in thousands, except per share data)

(Unaudited)

Three months ended July 31,

Six months ended July 31,

2026

2025

2026

2025

Sales and marketing expense on a GAAP basis

$    126,701

$    109,439

$    237,818

$    208,067

Stock-based compensation expense

(27,886)

(25,392)

(52,480)

(47,713)

Amortization of purchased intangibles

(2,720)

(2,890)

(5,051)

(5,685)

Sales and marketing expense on a non-GAAP basis

$     96,095

$     81,157

$    180,287

$    154,669

General and administrative expense on a GAAP basis

$     71,314

$     95,804

$    140,786

$    164,630

Stock-based compensation expense

(28,534)

(26,441)

(55,724)

(53,897)

Litigation settlement-related charges

—

(30,627)

—

(30,627)

General and administrative expense on a non-GAAP basis

$     42,780

$     38,736

$     85,062

$     80,106

Operating expense on a GAAP basis

$    420,933

$    397,920

$    809,845

$    749,407

Stock-based compensation expense

(118,640)

(105,221)

(221,987)

(202,947)

Amortization of purchased intangibles

(2,990)

(2,890)

(5,321)

(5,685)

Litigation settlement-related charges

—

(30,627)

—

(30,627)

Operating expense on a non-GAAP basis

$    299,303

$    259,182

$    582,537

$    510,148

Operating income on a GAAP basis

$    275,018

$    195,908

$    548,130

$    429,640

Stock-based compensation expense

136,803

121,966

256,062

234,176

Amortization of purchased intangibles

4,062

4,075

7,067

8,016

Litigation settlement-related charges

—

30,627

—

30,627

Operating income on a non-GAAP basis

$    415,883

$    352,576

$    811,259

$    702,459

Operating margin on a GAAP basis

29.6 %

24.8 %

30.3 %

27.8 %

Stock-based compensation expense

14.7

15.5

14.1

15.1

Amortization of purchased intangibles

0.5

0.5

0.4

0.5

Litigation settlement-related charges

—

3.9

—

2.0

Operating margin on a non-GAAP basis

44.8 %

44.7 %

44.8 %

45.4 %

Net income on a GAAP basis

$    273,429

$    200,309

$    534,365

$    428,499

Stock-based compensation expense

136,803

121,966

256,062

234,176

Amortization of purchased intangibles

4,062

4,075

7,067

8,016

Litigation settlement-related charges

—

30,627

—

30,627

Income tax effect on non-GAAP adjustments(6)

(26,882)

(23,572)

(38,945)

(40,085)

Net income on a non-GAAP basis

$    387,412

$    333,406

$    758,549

$    661,234

Diluted net income per share on a GAAP basis

$        1.66

$        1.19

$        3.22

$        2.56

Stock-based compensation expense

0.83

0.73

1.54

1.40

Amortization of purchased intangibles

0.02

0.02

0.04

0.05

Litigation settlement-related charges

—

0.18

—

0.18

Income tax effect on non-GAAP adjustments(6)

(0.16)

(0.13)

(0.23)

(0.24)

Diluted net income per share on a non-GAAP basis

$        2.35

$        1.99

$        4.57

$        3.95

________________________
(6) For the three and six months ended July 31, 2026 and 2025, management used an estimated annual effective non-GAAP tax rate of 21.0%.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/veeva-announces-fiscal-2027-second-quarter-results-302860933.html

SOURCE Veeva Systems

Continue Reading

Technology

Werfen launches a campaign to thank healthcare professionals and laboratories as part of its 60-year celebrations

Published

on

By

Through the short film ‘Thank You,’ featuring real patients, the campaign highlights the impact of in vitro diagnostics (IVD), which plays a key role in 70% of medical decisions worldwide and is crucial to patient survival and quality of lifeThe launch coincides with the company’s 60th anniversary, consolidating a six-decade trajectory to international leadership across its five clinical areas of specialized diagnostics

BARCELONA, Spain, Nov. 12, 2026 /PRNewswire/ — In Vitro Diagnostics (IVD) plays a crucial role in life-saving clinical decisions. To recognize and thank the healthcare professionals and laboratory teams who make this possible every day, Werfen has launched the ‘Thank You’ initiative. Launched on the occasion of its 60th anniversary, this is the company’s first corporate brand campaign centered entirely on its purpose of advancing patient care by delivering trusted and innovative specialized diagnostics.

Currently, IVD influences around 70% of clinical decisions worldwide, ranging from confirming compatibility in a kidney transplant to detecting chronic disease or monitoring patients during highly complex cardiac surgery. However, this analytical work largely takes place behind the scenes.

The central element in the campaign is a documentary short film, available at https://www.werfen.com/thankyou. With it, Werfen seeks to highlight the direct impact of having reliable and timely data, at the time of diagnosis and in the continuous management of diseases and people’s quality of life, focusing on improving patient outcomes through diagnostic precision.

The voice of patients and the true significance of diagnostics

The campaign gathers stories from real patients who have gone through complex health processes. Through their stories, patients express their gratitude to the healthcare professionals who interpreted their test results and provided the necessary clarity to determine the appropriate therapeutic path to manage their health.

Developed in collaboration with patient associations and non-profit organizations, the initiative gives visibility to the relevance of diagnostics in more than a dozen pathologies such as lupus, thalassemia, hemophilia, thrombosis episodes, rheumatoid arthritis, complex cardiac surgery, or kidney and liver transplants. All of them are severe medical conditions that represent Werfen’s five highly specialized clinical areas: Hemostasis, Acute Care Diagnostics, Transfusion, Autoimmunity, and Transplant.

In the words of Alejandro Risso, CEO of Werfen: “Sixty years ago, Werfen was born with a calling to stand alongside healthcare professionals in moments that mark a before and after in patients’ lives. Our responsibility is to provide maximum analytical precision so that professionals can make decisions with total confidence when it matters most.” To this, he adds: “Behind every diagnosis there is knowledge, experience, precision and, above all, people committed to improving and saving lives. With this campaign we want to bring these professionals to the forefront and thank them for a work that, after 60 years, continues to give meaning to ours.”

Six decades of commitment to specialized diagnostics

The campaign launch takes place during the company’s 60-year anniversary. Founded in Barcelona in 1966, Werfen has evolved to establish itself as a multinational group specialized in IVD, with presence in more than 30 countries, as well as its own R&D capacity and production centers in Europe and the United States.

Throughout this time, the company has strengthened its international presence through direct commercial expansion in key markets such as the United States and China, coupled with the progressive integration of specialized firms in its different clinical areas. This process culminated in 2024 with the strategic decision to concentrate all its resources and research on in vitro diagnostics, thereby reaffirming its commitment to continue providing greater certainty to the scientific and medical community.

Innovation has been one of Werfen’s pillars throughout its 60-year history. As a result of this commitment, in 2025 the company allocated 190 million euros to research and development to continue driving advances in the science of in vitro diagnostics.

In a field where scientific rigor, clinical relevance, and reliability are fundamental, Werfen combines innovation, experience, and talent to offer more effective diagnostics that help laboratories, hospitals, doctors, and healthcare professionals make better clinical decisions and improve people’s quality of life.

About Werfen

Founded in 1966, Werfen is a worldwide developer, manufacturer, and distributor of specialized diagnostic instruments, related reagents, automation workcells, and data management solutions for use primarily in hospitals and independent clinical laboratories. The company’s business lines include Coagulation, Acute Care Diagnostics, Transfusion, Autoimmunity, and Transplant. With a workforce of over 7,130 people, Werfen operates directly in more than 30 countries and in over 100 territories through distributors. For more information, visit werfen.com.

Legal Disclaimer 

This document contains forward-looking statements regarding our future business, financial data, and future events related to Werfen that may constitute forward-looking estimates. These estimates can be identified by words such as “expectation,” “forward-looking,” “anticipation,” “intention,” “plan,” “belief,” “seek,” “estimate,” “future,” “project,” or words of similar meaning. We may also make forward-looking estimates in other reports, presentations, and press releases. Additionally, our representatives may occasionally make oral statements with forward-looking estimates. These estimates are based on our current expectations and certain assumptions, many of which are beyond the corporation’s control and are subject to a series of risks and uncertainties. In the event that any of such risks or uncertainties materialize or underlying expectations fail to occur, Werfen’s results, performance, or achievements could vary substantially (positively or negatively) from those explicitly or implicitly described in the relevant forward-looking estimate. Werfen assumes no obligation to revise or update any forward-looking estimates previously made.

SOURCE Werfen

Continue Reading

Technology

Robo.ai to Advance Its Middle East Public Safety Strategy at World Police Summit 2026

Published

on

By

Subsidiaries ALIF Holding and Neurovia AI to present visual data technology and outline plans for maritime systems and advanced materials at Stand AH5D

DUBAI, UAE, Nov. 12, 2026 /PRNewswire/ — Robo.ai Inc. (Nasdaq: AIIO) (“Robo.ai” or the “Company”) today announced that its controlled subsidiary ALIF Holding, an Abu Dhabi-based industrial group, together with Neurovia AI, another subsidiary of the Company, will participate in the World Police Summit on November 16–18, 2026, at the Dubai World Trade Centre. Participation in the Summit supports the Company’s strategy of bringing AI infrastructure and local industrial capabilities to government, public safety and mission-critical sectors in the UAE and wider Middle East.

Hosted by Dubai Police and organized by DXB LIVE, the Summit is a major Middle East platform that brings together international law enforcement leaders, public safety decision-makers and technology companies. Its fifth edition, themed “Connected for Impact,” offers Robo.ai a focused opportunity to engage with prospective customers and technology partners on their operational needs.

At Stand AH5D, Neurovia AI will present NeuroStream™, its visual data optimization platform designed to reduce video storage and transmission requirements while preserving information needed for downstream applications. In a previously reported demonstration, a 12.15 GB, 4K video file was reduced to 421 MB, a decrease of more than 96%. This result reflects a specific demonstration; actual performance and benefits depend on deployment conditions and use-case validation.

ALIF Holding will also outline plans for intelligent maritime systems for ports, coastlines and critical facilities through the proposed ALIF Maritec, and for carbon fiber materials and UAE manufacturing capabilities through the proposed ALIF Composites. Together, these initiatives reflect Robo.ai’s strategy of connecting efficient AI data infrastructure with intelligent systems and local industrial development.

This approach aligns with the UAE National Strategy for Artificial Intelligence 2031 and the technology-enabled public safety ambitions of “We the UAE 2031.” At the Summit, Robo.ai aims to deepen customer engagement and develop partnerships that can support commercial applications and long-term business growth.

About ALIF Holding

ALIF Holding is Robo.ai’s Abu Dhabi-based industrial group, focused on intelligent software, intelligent equipment and the development of local industrial capabilities. Through international technology collaboration and local integration, it aims to develop intelligent systems and products for governments, critical infrastructure and industrial customers.

About Neurovia AI

Neurovia AI is an Abu Dhabi-headquartered artificial intelligence infrastructure and visual data processing company, operating as a wholly owned subsidiary of Robo.ai Inc. (Nasdaq: AIIO).Through its flagship platform, NeuroStream™, the company develops intelligent data optimization solutions designed to reduce infrastructure demands while supporting efficient, secure and scalable AI applications.Neurovia AI serves the evolving needs of government, enterprise and data-intensive industries, advancing its vision of scaling sustainable AI infrastructure.

About Robo.ai Inc.

Robo.ai Inc. (Nasdaq: AIIO), headquartered in Dubai, United Arab Emirates, is a Nasdaq-listed technology group building intelligent infrastructure across four platforms: artificial intelligence; robotics and smart mobility; advanced manufacturing; and digital assets and capital. Its industrial group, ALIF Holding, is dedicated to building intelligent industries through the development, integration and manufacturing of AI systems, serving government, public sector and mission-critical domains. Through its subsidiary Neurovia AI, the Company develops AI software and visual data infrastructure. Quantum Core Capital (“QC Capital”), its AI-powered deep-tech holding and venture-building platform, incubates, invests in and operates businesses across artificial intelligence, robotics, digital infrastructure and the next-generation digital economy.

Forward-Looking Statements

This release includes forward-looking statements under the U.S. Private Securities Litigation Reform Act of 1995 concerning exhibition plans, technology benefits, proposed projects, local manufacturing, partnerships and business growth. These statements reflect current expectations and are not guarantees of future performance. Actual outcomes may differ materially due to technology validation and commercialization, customer demand, competition, funding, project formation, permits, equipment, site readiness and execution risks, as well as the Company’s financial condition and other risks described in its SEC filings. Proposed projects remain subject to development and operational readiness. These statements speak only as of the date of this release, and, except as required by applicable law, Robo.ai undertakes no obligation to update or revise them.

Media Contacts

ALIF Holding Corporate Communications
Email: info@alifholding.ai  |  Website: www.alifholding.ai

Neurovia AI | Marketing & Communications
Email: info@neuroviaai.com Website: www.neuroviaai.com

Robo.ai Inc. Corporate Communications
Email: pr@roboai.group  |  Website: www.roboai.group

View original content to download multimedia:https://www.prnewswire.com/news-releases/roboai-to-advance-its-middle-east-public-safety-strategy-at-world-police-summit-2026-302937724.html

SOURCE Robo.ai Inc.

Continue Reading

Technology

CodeWall Accelerates Expansion, Names Former Orca Security VP as CTO

Published

on

By

CodeWall is scaling its engineering team and autonomous attack platform with an ambition to make offensive security as fundamental as firewalls and endpoint protection.

LONDON, Nov. 12, 2026 /PRNewswire/ — CodeWall is accelerating its expansion to make autonomous offensive security a permanent enterprise capability. Following its $4 million pre-seed round, the company is scaling engineering and expanding what its autonomous attack agents can investigate, today announcing former Orca Security VP of Engineering Peter Spellward as Chief Technology Officer to lead that effort.

Spellward brings experience building security technology and the organisations behind it. At cloud security unicorn Orca Security, he served as VP of Engineering, led UK research and development and helped scale its engineering organisation. He also co-founded Innovode, whose technology was acquired by CloudLock, subsequently acquired by Cisco.

“AI is giving attackers extraordinary speed and reach. We’re building to put that advantage in the hands of enterprise security teams,” said Paul Price, founder and CEO of CodeWall. “We intend to move aggressively: hire exceptional engineers, expand what our agents can take on and bring this capability to more enterprises. Peter brings experience building the products and engineering organisations that make that expansion possible.”

Spellward leads technology strategy and engineering, with a focus on accelerating delivery, broadening platform coverage and strengthening how agents coordinate complex investigations.

“The engineering challenge is to turn sophisticated attacker behaviour into a capability enterprises can depend on continuously,” said Peter Spellward, CTO of CodeWall. “That means agents that can safely reason through unfamiliar systems, build on each other’s discoveries and produce evidence defenders can trust. We’re building the team and architecture to deliver that at scale.”

CodeWall’s agents investigate enterprise environments from an external attacker’s perspective. They share discoveries and follow weaknesses across connected systems to establish what could actually be compromised, supporting continued investigation and retesting as customer environments change.

The company is already working with large banks and fintech firms, including Axos Financial, to deliver autonomous offensive testing and verified evidence of exploitable attack paths.

“Every enterprise will have an attacker working for it. It will be as essential as a firewall or endpoint protection,” added Price. “We intend to make CodeWall the standard. That’s the scale we’re hiring for, building for and going after.”

To learn more or explore open roles, visit codewall.ai.

About CodeWall

CodeWall builds autonomous offensive security technology for enterprises. Its agents investigate externally accessible systems, trace exploitable weaknesses and provide verified evidence to help defenders address their exposure. The platform supports sustained adversarial testing within customer-defined guardrails.

Media Contact:
press@codewall.ai

 

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/codewall-accelerates-expansion-names-former-orca-security-vp-as-cto-302937370.html

Continue Reading

Trending